Published in Mediators Inflamm on February 01, 2017
Dysregulation of pulmonary endothelial protein C receptor and thrombomodulin in severe falciparum malaria-associated ARDS relevant to hemozoin. PLoS One (2017) 0.75
IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells. J Exp Clin Cancer Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 8.19
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 7.82
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 5.99
The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 5.11
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol (2007) 4.66
WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol (2004) 3.55
IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 3.12
Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol (2003) 3.07
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature (2014) 2.58
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity (2012) 2.47
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2003) 2.45
IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol (2009) 2.39
The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol (2004) 2.09
IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res (2003) 2.08
Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A (1997) 2.02
IL-21 mediates suppressive effects via its induction of IL-10. J Immunol (2009) 2.00
Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol (2008) 1.92
Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med (2014) 1.91
IL-27 limits IL-2 production during Th1 differentiation. J Immunol (2006) 1.89
Potent antitumor activity of interleukin-27. Cancer Res (2004) 1.80
Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med (2006) 1.78
IL-2: the first effective immunotherapy for human cancer. J Immunol (2014) 1.71
Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis (2008) 1.70
An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol (2004) 1.66
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov (2014) 1.62
IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol (2004) 1.58
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 1.50
Antiangiogenic and antitumor activities of IL-27. J Immunol (2006) 1.50
Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol (2005) 1.50
IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol (2007) 1.50
Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J Exp Med (2007) 1.47
IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol (2004) 1.46
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
Cutting edge: T-bet and IL-27R are critical for in vivo IFN-gamma production by CD8 T cells during infection. J Immunol (2008) 1.36
IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. J Immunol (2006) 1.34
The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J Immunol (2009) 1.34
Antiproliferative activity of IL-27 on melanoma. J Immunol (2008) 1.33
IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS (2008) 1.33
IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J Immunol (2007) 1.26
Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol (2004) 1.25
Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol (2011) 1.24
IFN-beta modulates the response to TLR stimulation in human DC: involvement of IFN regulatory factor-1 (IRF-1) in IL-27 gene expression. Eur J Immunol (2007) 1.22
Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood (2006) 1.21
Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol (2005) 1.20
Differential effects of IL-27 on human B cell subsets. J Immunol (2006) 1.18
The immunobiology of interleukin-27. Annu Rev Immunol (2015) 1.18
IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol (2010) 1.13
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat Immunol (2015) 1.08
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res (2013) 1.07
Induction of IgG2a class switching in B cells by IL-27. J Immunol (2004) 1.07
Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology (2009) 1.07
Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res (2010) 1.07
Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat Immunol (2015) 1.06
IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J Immunol (2012) 1.06
IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol (2013) 1.06
IL-27 renders DC immunosuppressive by induction of B7-H1. J Leukoc Biol (2011) 1.05
Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res (2012) 1.05
Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res (2009) 1.02
Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol (2012) 1.02
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem (2012) 1.01
No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun (2005) 0.98
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol (2015) 0.96
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res (2008) 0.95
Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27. Blood (2007) 0.95
The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology (2009) 0.94
IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev (2015) 0.94
An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun (2015) 0.93
IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization. Proc Natl Acad Sci U S A (2014) 0.93
Interleukin-35 Limits Anti-Tumor Immunity. Immunity (2016) 0.93
Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas. J Pathol (2006) 0.93
Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res (2009) 0.93
Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology (2013) 0.91
Interleukin-27: biological properties and clinical application. Arch Immunol Ther Exp (Warsz) (2010) 0.91
Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens (2001) 0.91
Immunotherapeutic applications of IL-15. Immunotherapy (2012) 0.90
The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget (2014) 0.90
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator. Hum Immunol (2007) 0.89
Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer. Oncotarget (2015) 0.89
IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS One (2013) 0.89
Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. Clin Cancer Res (2013) 0.88
Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response. Proc Natl Acad Sci U S A (2012) 0.87
IL-27 Regulates IL-18 binding protein in skin resident cells. PLoS One (2012) 0.87
IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J Immunol (2008) 0.87